Frequently searched
↑ ↓ to move · Enter to open · Esc to closeSynonyms and typos are matched
Trial site
Completed
Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)
NCT03903562· Phase 3· Merck Sharp & Dohme LLC· Source
Site data: ClinicalTrials.govUpdated 12 Nov 2026
Report an error